| a dna/mva-based candidate human immunodeficiency virus vaccine for kenya induces multi-specific t cell responses in rhesus macaques. | the minimum requirement for candidate human immunodeficiency virus (hiv) vaccines to enter clinical evaluation in humans should be their demonstrable immunogenicity in non-human primates: induction of antibodies neutralizing primary hiv isolates or elicitation of broad t cell-mediated immune responses. here, we showed in rhesus macaques that the very same vaccines that had entered clinical trials in oxford and nairobi, plasmid pthr.hiva dna and recombinant modified vaccinia virus ankara mva.hiva ... | 2002 | 11752703 |
| development of a dna-mva/hiva vaccine for kenya. | without going into the details of the devastation that human immunodeficiency virus (hiv) infection causes especially in the developing world, the best hope for changing the course of this epidemic is development of a safe, effective, accessible prophylactic hiv vaccine. while the inaccessibility of potentially neutralising epitopes on primary hiv isolates has hampered the development of envelope-based vaccines, there is a number of new potent technologies capable of inducing high levels of circ ... | 2002 | 11983261 |